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The African Programme for Onchocerciasis Control (APOC) has been described as one of the
most successful public-private partnerships for health in Africa [1]. The Programme helps the
governments of 20 onchocerciasis-endemic countries to develop sustainable delivery of iver-
mectin treatment in order to control and eliminate river blindness [2]. APOC is one of a very
few programs that the WHO implements directly, in this case through the Regional Office for
Africa (AFRO) and the APOC Secretariat established in Ouagadougou, Burkina Faso. As the
Executing Agency of APOC, WHO is responsible for the development of procedures for imple-
menting community-directed treatment with ivermectin (CDTi), approving funding to coun-
tries, maintaining surveillance, and ensuring monitoring and evaluation [3]. The Executing
Agency supports governments directly in this role, aided by a group of 15 Non-Governmental
Development Organizations (NGDOs), operating nationally, regionally, and globally [4]. The
15 NGDOs include Charitable Society for Social Welfare, Christoffel-Blindenmission (CBM),
Helen Keller International (HKI), Light the World, Mectizan Donation Program (MDP), Mis-
sion to Save the Helpless (MITOSATH), Organisation pour la Prévention de la Cécité (OPC),
Sightsavers International, United Front Against Riverblindness (UFAR), Interchurch Medical
Assistance (IMA)World Health, Lions Clubs International Foundation, Malaria Consortium,
Schistosomiasis Control Initiative, The Carter Center, and The United States Fund for UNICEF.
The funding for national onchocerciasis control comes from the countries and civil society, with
additional funding from APOC through contributions frommore than 30 development part-
ners to a Trust Fund that theWorld Bank manages in its role as Fiscal Agent.
Scheduled to close in 2015, the main governing body of APOC decided to set up a new pro-
gramme for a ten-year period from 2016, actively seeking to eliminate river blindness from
most of Africa by 2025 and, by strengthening the same health system that successfully delivered
treatment for river blindness, seeking to also eliminate lymphatic filariasis and co-implement
treatments for the five other major preventable neglected tropical diseases (NTDs) that can be
addressed through mass drug administration. Plans are underway to transform APOC beyond
2015 and transition from a single-disease entity to an expanded regional NTD initiative [5].
This article is one of a series developed by the partnership of agencies, institutions, and indi-
viduals that make up APOC. This article is written from the perspective of the Fiscal Agent
(the APOC Team at the World Bank) and should be read in conjunction with the correspond-
ing articles in this series that examine the depth and diversity of the river blindness partnership,
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which includes the Executing Agency (World Health Organization) [3], civil society [4], and
the Mectizan Donation Program [6].
The Origins of Financial Management of Onchocerciasis Control in
Africa
The origins of financial support for onchocerciasis control can be traced back to those of
World Bank’s support for health in general. The International Bank for Reconstruction and
Development (IBRD)—the first institution of what was later to become the World Bank Group
(WBG)—was founded in 1944 with the primary aim of supporting post—World War II recon-
struction and economic development. In the 1960s, the World Bank extended its remit to spe-
cific support for low-income countries by the provision of concessional credits and grants
through the International Development Association (IDA).
The main focus of the World Bank’s support then was on infrastructure projects. The earli-
est grants relevant to health and human development were minor investments in water and
sanitation projects in the 1960s and support for family planning in the 1970s [7]. In January
1972, the World Bank published a report, Possible Bank Actions on Malnutrition Problems,
which led to the establishment of a nutrition department within the World Bank, and in 1975
the World Bank released its firstHealth Policy paper creating the combined health, nutrition,
and population structure that exists today as the HNP Network. The World Bank’s health port-
folio has steadily increased since those early beginnings: from an average of US$25 million per
year in the 1970s, to US$1.4 billion per year in the 1990s, and rising to US$1.7 billion in the
2000s [8].
It was against this background that support for the Onchocerciasis Control Programme for
West Africa (OCP) was launched in 1974, arguably the first health-focused project that the
World Bank supported [9]. Political support for this step has been attributed to a visit made by
the then—World Bank President Robert McNamara to Burkina Faso, where he was shocked to
see numbers of blind adults being led with a stick by their children, an iconic image of river
blindness that then, as now, did much to raise public awareness of the disease. Bronze statues
depicting this image are displayed in multiple institutions around the world that have made an
important contribution to the control of river blindness.
The Onchocerciasis Control Programme for West Africa (OCP) and
the Evolution of the African Programme for Onchocerciasis Control
(APOC)
In 1974, OCP used vector control with larvicides to control river blindness in 11 countries in
West Africa. The 11 countries included Benin, Burkina Faso, Cote d'Ivoire, Ghana, Guinea,
Guinea Bissau, Mali, Niger, Senegal, Sierra Leone, and Togo. The Executing Agency was
WHO, with the World Bank working with other development agencies as Fiscal Agent, essen-
tially under the same division of labor as exists today with APOC. OCP was very successful in
controlling the disease, freeing 18 million children from the risk of blindness and reclaiming
some 25 million hectares of abandoned arable land—enough to feed about 17 million people
[10]. But expansion of OCP to the other 20 onchocerciasis-endemic countries in Africa was
not feasible, as costs for the OCP countries alone had spiraled to nearly a billion US dollars
(Fig 1) and the riverine vector control methods for the savannah onchocerciasis in the OCP
area were not applicable to the forest onchocerciasis found in other regions. These countries in-
cluded Angola, Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Re-
public of the Congo, Equatorial Guinea, Ethiopia, Gabon, Kenya, Liberia, Malawi, Mozambique,
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Nigeria, Rwanda, Sudan, Tanzania, Uganda, and South Sudan (which became the 20th partici-
pating country as of 2011).
In 1987, a new treatment-based strategy emerged, based on the recognition that the drug
ivermectin had efficacy against onchocerciasis and the extraordinary commitment by Merck &
Co., Inc., (MSD outside the US and Canada) to donate ivermectin (Mectizan), “as much as is
necessary for as long as is necessary” [11]. Based on the effectiveness and lower cost of the
treatment approach, APOC was launched in 1995, and in 2002 was extended into a second
phase, APOC II, through 2015. For 40 years, the World Bank has played a key role as the fiscal
agent for OCP and then APOC, bringing to bear its comparative advantage in fiscal governance
by managing the APOC Trust Fund, which channels the contributions of more than 30 donors,
including governments, foundations, philanthropists, and the private sector, to APOC.
The APOC Trust Fund
The key financial instrument for managing APOC finances is its Trust Fund, a mechanism
through which several donors can co-finance international development projects. The first
World Bank trust fund was established in 1960 to finance the Indus Basin Project in Pakistan,
providing US$90 million over 15 years. Trust fund management today plays a major role in
World Bank support for development, with fund flows totaling US$29.1 billion in 2011 [12].
Some of the largest of these funds support health investments, such as the US$2.45 billion
Global Fund to Fight Aids, Tuberculosis and Malaria (GFATM); the US$211 million Interna-
tional Finance Facility for Immunization (IFFIm); and the US$137 million Pilot Advance Mar-
ket Commitment for Vaccines against Pneumococcal Diseases (AMC) [13]. The trust fund
established in 1974 to help control onchocerciasis, covering both the OCP and the APOC peri-
od, has accumulated receipts to date of over US$1.2 billion (Fig 1).
For about half the trust funds, those that are Bank-Executed or are Recipient-Executed with
bank oversight, the World Bank not only manages the fund but also implements or supervises
the activities that are financed by the fund. In these types of funds the World Bank is responsi-
ble for both financial and programmatic functions, ultimately exercising oversight over the op-
erational use of the funds [14].
Fig 1. APOC and OCP total cumulative donations (1974–2013).
doi:10.1371/journal.pntd.0003508.g001
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For the remaining trust funds, the World Bank serves as a trustee with responsibility for the
fiduciary oversight of the funds. These are termed Financial Intermediary Funds (FIF), and the
APOC Trust Fund and the OCP Trust Fund before it are of this type. For all FIFs, the World
Bank provides a set of agreed financial services that involve receiving, holding, and investing
contributed funds, and then transferring those funds when requested by the Executing Agency.
Under some FIFs, the Bank also provides other financial services, such as bond issuance, hedg-
ing intermediation, and monetization (e.g., of carbon credits). FIF Trusteeship does involve fi-
duciary oversight, but not the actual use of the funds, which is the responsibility of the
implementing agency [14]. Fig 2 illustrates the flow of funds in the case of the APOC and OCP
Trust Funds: the Fiscal Agent (World Bank) receives, holds, and invests funds from develop-
ment partners and, on request, transfers these funds to the Executing Agency (WHO), from
which they flow to the implementing levels (the participating countries and the APOC
Secretariat).
APOCGovernance
APOC has strong representative governance. The ultimate decision-maker is the Joint Action
Forum (JAF), which is comprised of the 20 governments of the participating countries repre-
sented at the level of Ministers of Health, as well as representatives of more than 30 contribut-
ing development partners, co-sponsoring agencies, and 15 NGDOs (that also formed into the
NGDO Coordination Group for Onchocerciasis Control) that help implement and support the
program [15]. The annual meeting of JAF makes the main policy decisions, in particular, the
approval of plans of action and budgets, in accordance with legal proceedings overseen by the
WHO Secretariat. There have been 19 meetings of the JAF up to the end of 2013.
To provide continuous oversight of the implementation of these policy decisions, a Com-
mittee of Sponsoring Agencies (CSA) meets four times per year to review reports of various or-
gans and participants, acting on behalf of the JAF when required. The CSA is currently chaired
by WHO and includes representatives of WHO (the Executing Agency), World Bank (the Fis-
cal Agent, also representing the contributing development partners), the African Development
Bank, the NGDO coordination group, the Mectizan Donation Program and Merck & Co., Inc.,
with the assistance of the WHO’s Legal Office. There have been 145 meetings of the CSA
through July 2014. This institutional framework is completed by a Technical Consultative
Fig 2. The flow of funds from donors to national and regional APOC activities.
doi:10.1371/journal.pntd.0003508.g002
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Committee (TCC) meeting twice a year at APOC headquarters and providing technical advice
to the Programme’s management.
The APOC Secretariat (as Executing Agency) is responsible for the implementation of activ-
ities and for initiating the budget process (Fig 3). The APOC Secretariat takes the lead in pre-
paring a multi-year Plan of Action for APOC and uses this to develop an indicative budget to
implement the multi-year plan (the APOC Plan of Action and Budget, PAB). To aid financial
planning, a detailed budget is prepared on a two-year basis and provided to the CSA for the
next step in the budget process. The biennial PAB is subject to scrutiny by the CSA, and a final
version, agreed between the CSA and the APOC Secretariat, is presented to the JAF for formal
approval. All financial transfers within APOC systems are made on the basis of this approved
PAB.
The Role of the Fiscal Agent
The primary role of the World Bank is as the fiscal agent for APOC. The World Bank is repre-
sented on different organs of APOC governance, but does not define or approve WHO requests
for funding. In particular, the World Bank does not prepare or approve the PAB (Fig 3), al-
though it is part of the oversight and scrutiny of the process. There is therefore a clear separa-
tion (within the APOC organizational framework) between the fiscal and implementing roles.
The PAB prepared by the APOC Secretariat and approved by JAF is the basis of all financial
actions by the Fiscal Agent. The current PAB covers the period 2008–2015 (Fig 4) and indicates
the anticipated expenditure to implement APOC activities over that period. A more detailed bi-
ennial budget, again prepared by the APOC Secretariat and approved by the JAF, guides precise
expenditures over a two-year cycle. Based on requests from the WHO within the approved
budget, and in accordance with the approved PAB, the World Bank transfers funds from the
APOC Trust Fund to the WHO so that the APOC Secretariat may in turn support implementa-
tion at the regional and country levels.
The key instrument, which sets out the relationship between the fiduciary role of the World
Bank and the implementing role of WHO, is the Memorandum for APOC. The Memorandum
stipulates the role of the World Bank as providing fiduciary (legal) oversight of the APOC
Trust Fund and that of WHO as ensuring the implementation of activities approved by APOC
governance. This instrument is the basis of the agreement between contributing parties and the
participating countries. In practice, decisions of a legal nature are made upon the advice of the
World Bank and WHO legal teams. The World Bank ensures that the pooled trust fund has an
adequate amount to cover the scheduled withdrawal requests fromWHO and monitors and
Fig 3. Process of budget preparation, approval, andmonitoring.
doi:10.1371/journal.pntd.0003508.g003
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reports to the APOC Governing Bodies on the flow of funds for the program, helping ensure
that these flows respond to the PAB approved by the JAF.
The World Bank also plays a role, in collaboration with the other APOC partners, in re-
source mobilization. Once the PAB has been approved by the JAF, the World Bank leads a
joint effort by the APOC partnership to identify income and pledges of income for the duration
of the PAB. The World Bank aims to respond effectively to the needs of existing development
partners and to work with them and new partners to increase revenues, in particular when the
JAF determines a need for additional support. All new development partners contributing to
the Trust Fund are subject to World Bank requirements for due diligence and sign the standard
Memorandum for APOC.
Throughout the duration of the OCP and APOC Trust Funds, both programs have enjoyed
the enthusiastic support of multiple development partners that have been able to match the
budgetary requests from the JAF. Until the decision to transform APOC was taken, funding
and pledges of funding fully covered the PAB through the scheduled sunset of APOC in 2015.
The World Bank has a specific responsibility to the contributing development partners for
the fiduciary oversight of the Trust Fund. In this context, the External Auditor of WHO con-
ducts an annual independent audit of APOC’s financial statements, reporting to contributors
at the JAF. The Fiscal Agent reports regularly to the contributing development partners on the
progress of the CSA meetings and annually presents to the JAF an analysis of the fiscal health
of the Trust Fund and its status in respect to the PAB.
In addition to the management role, the World Bank is itself a contributor to the Trust
Fund through its Global Partnership Programs (GPP) facility (Fig 5). Apart from this direct
support to APOC, the GPP has also provided substantial indirect support to the work of WHO
and the APOC Secretariat through its contributions to the Programme for Research and Train-
ing for Tropical Diseases (TDR), founded in 1975 by the World Health Organization with the
United Nations Children's Fund (UNICEF), the United Nations Development Program
(UNDP), and the World Bank. Research supported by TDR has contributed to the
Fig 4. Current APOC strategic plan and budget, 2008–2015.
doi:10.1371/journal.pntd.0003508.g004
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development of onchocerciasis control strategies, especially the work in collaboration with
Merck and the Mectizan Donation Program, which was pivotal in the development of the use
of ivermectin for onchocerciasis and in the development of the current CDTi
mechanism, respectively.
Financing of the APOC Trust Fund
The APOC Trust Fund is supported entirely through voluntary contributions from develop-
ment partners that have been formally admitted as contributors to the Program. The Trust
Fund was established in 1995 and is expected to have managed approximately US$258 million
by 2015. Fig 6 shows the annual receipts since 1996, averaging US$13.0 million per annum.
Fig 5. Contributions to the trust fund based on donor characteristics.
doi:10.1371/journal.pntd.0003508.g005
Fig 6. Total receipts: APOC I and II (1996–2015). Values from 1996–2011 have been deflated using the gross domestic product (GDP) deflator. 2012–
2015 values represent the nominal amount.
doi:10.1371/journal.pntd.0003508.g006
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Together, the OCP and APOC trust funds have managed more than US$1.2 billion in support
of river blindness control over the last 30 years (Fig 1).
Effective control requires that treatment programs are sustained over a period of many
years, and hence consistency, loyalty, and timeliness of contributions have been important fac-
tors in the success of APOC. While the scale of these large donations has been very important
to the success of the program, there are other factors that have made some relatively smaller
donations critical to the rollout of APOC. Several development partners, including quite a few
of those making relatively small contributions, have individually provided the type of reliable
and predictable support that has made long-term intervention possible (Fig 7). For instance,
the Kuwait Fund has been a consistent donor since the beginning of the OCP program and has
continued throughout APOC. Taken together, these relatively smaller contributions total an
important 20% of the overall budget.
A key contributor to the success of APOC is the diversity and depth of its public-private
partnership, which includes multilateral and bilateral agencies, development institutions, inter-
national organizations, private foundations, civil society and the private sector. Bilateral agen-
cies are the largest single source of contributions (Fig 5). To date, the Governments of 20
countries have contributed to APOC Trust Fund, which contradicts the anecdotal view that
there has been limited political interest in contributing to the control of NTDs (Fig 8).
Overall, 34 development partners have contributed to the APOC Trust Fund. Seven of these
partners—World Bank, the United States, African Development Bank, Merck, Canada, the
Netherlands, and the United Kingdom—have together contributed 80% of the total funds
Fig 7. Annual contributions by selected donors during the period 1996–2015.
doi:10.1371/journal.pntd.0003508.g007
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received by the Trust Fund. Some of the reasons why these partners have supported APOC so
strongly are suggested by statements made by representatives of these organizations (Box 1).
While the majority of support to the APOC Trust Fund is from public funds, private sector
contributions make up a quarter of the total. Notably, this includes direct financial contribu-
tions from Merck (US$25 million, 2008–2015), which are additional to the value of the treat-
ment donated through the Mectizan Donation Program. The annual value of treatment
contributed by Merck to APOC, calculated at $1.50 per tablet in 2001, is estimated to be $146.6
million [16]. Since the treatment is donated, delivery of ivermectin is exceptional value
for money.
It is worth noting that both the Fiscal Agent and the Executing Agency are also contributors.
The World Bank and WHOmake no charges on the Trust Fund; all of their services are sup-
ported directly by the World Bank budget. The World Bank does not levy any overhead on the
income to the Trust Fund, and therefore 100% of the contributions enter the fund. In fact, the
held funds typically augment, pending transfer to WHO, as the World Bank Treasury invests
the funds prudently, when investment is allowed by the donor, as part of its overall manage-
ment. To date, APOC funds have accrued an additional US$9.6 million in income from
this source.
Fig 8. Contributions by APOC development partners to the Africa Regional Trust Fund for River Blindness, 1995–mid-2013. Total funds mobilized
from 1995 to present: $225 million. In nominal US dollars. Other: Australia, BADEA, Caritasverband, Champalimaud Foundation, END Fund, Finland,
Germany, Gulbenkian Foundation, Ireland, Japan, Kitosath Institute, MITOSATH, Norway, OFID, Poland, Portugal, Sabin Vaccine Institute, Sightsavers,
Slovenia, UNDP, andWHO.
doi:10.1371/journal.pntd.0003508.g008
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Box 1. Why Do the “Big Seven” Donors Support APOC?
World Bank
“The APOC program is one of the most successful public-private partnerships in health
in Africa.” Shanta Devarajan, Chief Economist, The World Bank Africa Region.
United States (USAID)
“The United States today is joining more than 40 non-governmental organizations, aca-
demic institutions, global health and civil society organizations to hail historic progress,
celebrate champions, and underscore continuing challenges in the global fight against
diseases affecting the world’s poorest and most marginal populations.”US Agency for In-
ternational Development (USAID) Press Office.
African Development Bank (ADB)
“The challenge is the need to strengthen the successful public-private partnership real-
ized by APOC which could only maintain all the gain obtained during more than 30
years for controlling Onchocerciasis. Among the major and sustainable gain is the reduc-
tion of inequalities and disparities that will lead to poverty alleviation, economic develop-
ment, productivity growth, and social returns.” Office of the Principal Health Analyst,
Human Development Department, Health Division, African Development Bank Group.
Merck
"We are pleased to augment our unwavering commitment to donate MECTIZAN (iver-
mectin) to all who need it, wherever needed, until river blindness is eliminated, by pro-
viding financial support to APOC. Only through partnership—working collaboratively
and harnessing our complementary skills and resources—can we effectively address the
most pressing global public health challenges." Kenneth C. Frazier, Chairman, President
and Chief Executive Officer, Merck.
The Netherlands
“APOC has been very instrumental in bringing health, and in particular health systems,
on the agenda of the Bank. The Programme made it clear that health is not just a ‘debit’
but a true asset, worth investing in. Large areas of land that were abandoned were used
again for agriculture once river blindness had successfully been beaten. It proved that a
bank could and should play a natural role in health Programs at global and country level.
Not just as a trustworthy accountholder, but as a partner.” Office of Head of the Health
and Aid Division, Social Development Department, Ministry of Foreign Affairs, Govern-
ment of the Netherlands.
United Kingdom (DFID)
“It is a tragedy that the lives of millions of the world’s poorest people are still being de-
stroyed by these ancient and avoidable tropical diseases (NTDs) when we have the
means to tackle them. . . The world is increasingly coming together to build on the long-
standing commitment of the pharmaceutical industry to rid the world of these terrible
diseases which disable, blind, and kill millions every year. . . British support will take the
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The Contribution of the APOC Trust Fund to National Control
Programs
The primary focus of support for national health systems in a given country is the national
budget. In the case of onchocerciasis, three main channels through which development assis-
tance is provided to support national health efforts to achieve onchocerciasis control can be
identified: first, through bilateral aid to government health budgets (e.g., from bilateral, inter-
governmental, and multilateral development agencies); second, through the regional trust fund
created by APOC, receiving funding from multiple sources within and beyond the region; and
third, indirect support from technical and civil society organizations (NGDOs), such as mem-
bers of the NGDO Coordinating Group and technical assistance organizations, which them-
selves are supported by bilateral and multilateral development partners, private sector
organizations, and their own fundraising efforts.
Fig 9 explores the relative contribution of these different channels to national onchocerciasis
control efforts. Obtaining accurate data on budgetary commitments is difficult in general, and
particularly when attempting to separate out support for a single intervention delivered
neglected out of neglected tropical diseases and will not just save lives—but transform
lives.” Stephen O’Brien, International Development Minister.
Fig 9. Sources of investment in national onchocerciasis control programs.
doi:10.1371/journal.pntd.0003508.g009
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through a health system, such as delivering treatment for onchocerciasis. Work supported by
USAID is contributing to this area through the Tool for Integrated Planning and Costing
(TIPAC), and WHO/AFRO has recently undertaken a regional costing exercise in 32 countries,
based on national plans. At the request of the participating countries on the JAF of APOC, the
African Development Bank and the World Bank are providing technical assistance to the
APOC Secretariat to help countries estimate their current investments in onchocerciasis con-
trol. The countries have asked for this assistance to help them track their specific investment in
onchocerciasis and in NTD control generally. According to the preliminary estimates of invest-
ment in onchocerciasis control presented in Fig 9, government investments, including bilateral
budget support, currently cover about 31% of the total; 14% is provided by indirect invest-
ments, principally via civil society; and 55% is through the APOC channels.
The analysis of the national budgets shows the important contribution of APOC to oncho-
cerciasis control, but simultaneously indicates that there is some way to go before govern-
ments sustain their own programs. The accumulating evidence suggests that in some
countries there is a trend for increases in the level of government contributions (Fig 10). Un-
surprisingly, this trend is clearest for the more stable counties with growing economies, and it
seems likely that assistance will continue to be required by countries affected by conflict and
other social shocks.
Fig 10 shows the national level of investment in onchocerciasis control over time, as re-
ported by governments to the APOC Secretariat. The total amount shown is the aggregate for
countries with stable economies and those countries emerging from conflict. The contribution
is shown to increase in both types of countries but at a greater rate in those with stable and
growing economies.
Fig 10. Contribution to national programs for onchocerciasis control (2006–2010).
doi:10.1371/journal.pntd.0003508.g010
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Strengths and Challenges of the Trust Fund Mechanism
The APOC Trust Fund serves a useful role as a central funding mechanism for the various con-
tributors and in particular for those who place a high premium on fiscal accountability. It pres-
ents a secure mechanism for obligating funds.
The fund benefits greatly from linking the comparative strengths of the World Bank and
WHO as fiscal and health-implementing agencies, respectively. This strong partnership be-
tween WHO and the World Bank is one of the greatest strengths of the fund, but it contributes
to what some donors consider a weakness since the inevitable layers of communication be-
tween the two entities present challenges for administration and reporting. This may not be an
issue for donors whose primary concerns are that their funds are secure and are being used to
implement closely supervised health programs, but it can be an issue for those donors seeking
to track a direct connection between their contribution and a specific action at the country
level.
Although all contributing parties (and participating governments) join into a standard
agreement about the APOC Trust Fund and its management, not all development partners
view the Fund in the same way. The history of the Fund shows that some partners use the Fund
as one among many ways of supporting onchocerciasis control and elimination programs in
Africa, while others use the Fund as their main and only conduit.
Looking Forward
In January 2012, a high-level meeting in London, “Uniting to Combat Neglected Tropical Dis-
eases,” announced a new public-private partnership to eliminate or control the seven prevent-
able NTDs. The meeting, co-chaired by Bill Gates, from the Bill & Melinda Gates Foundation,
and Sir AndrewWitty, CEO of GlaxoSmithKline, brought together 13 pharmaceutical compa-
nies as part of the continuing Gates-CEO Roundtable to enhance private sector investment in
public health challenges in low-income countries. The meeting led to the “London Declaration
on NTDs.” Among other pledges, the pharmaceutical companies collectively committed to do-
nate most of the drugs necessary to control and eliminate all seven preventable NTDs in low-
income countries.
At the 19th meeting of the JAF, held in Brazzaville in December 2013, and following a se-
ries of technical reviews requested by the participating countries over the previous two years,
it was decided to establish a new integrated NTD regional program in 2016. This new regional
initiative will actively seek to eliminate river blindness from most of Africa by 2025 and, by
strengthening the same health system that successfully delivered treatment for river blindness,
seek to co-implement treatments for the six other major preventable NTDs that can be ad-
dressed through mass drug administration. While the participating countries committed to
increase national contributions to make this possible, they also asked for external help to cre-
ate self-sustaining, community-based (including school-based) health systems that deal with
the full range of preventable NTDs and other diseases of the poor that can be addressed
through similar mechanisms. There was clear consensus among participating countries in
favor of focusing first on onchocerciasis and lymphatic filariasis elimination with co-imple-
mentation for NTDs and health system strengthening [17,18]. This view was also supported
by the 63rd Regional Committee of the WHO/AFRO. The institutional framework of this new
initiative, provisionally named the Programme for the Elimination of Neglected Diseases in
Africa (PENDA), will build upon the strength of APOC and is currently under discussion
among partners.
In this new climate, there are indications that the APOC Trust Fund is finding new ways to
contribute to onchocerciasis elimination and support the emerging NTD agenda (Box 2).
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Box 2. New and Emerging Trends in the APOC Trust Fund
Nigerian philanthropy reaches out to the rest of Africa
The Mission to Save the Helpless (MITOSATH) is a non-governmental development or-
ganization based in Jos, northern Nigeria, which has supported onchocerciasis control in
Nigeria since 1996. At JAF 16 in Abuja in 2010, General Theophilus Danjuma, the
Grand Patron and founder of MITOSATH, announced his intention to “extend the sup-
port of Nigerian philanthropy to control and eliminate river blindness throughout the
continent of Africa.”He followed up with a US$1 million contribution to the Trust Fund
and also challenged the government of Nigeria to follow his example. Building on the
momentum of its private citizens and foundations, in December 2011, at a meeting of
the APOC governing body (JAF) in Kuwait City, the government of Nigeria pledged US
$5 million to the Trust Fund.
International recognition for the work of APOC
The global relevance of APOC’s work was recognized in 2011 with the prestigious Antó-
nio Champalimaud Vision Award from the Champalimaud Foundation in Lisbon, Por-
tugal. This biennial award for the alleviation of visual problems in developing countries,
is supported by the “Vision 2020: Right to Sight” initiative of the World Health Organi-
zation and the International Agency for the Prevention of Blindness. The Foundation
President, Leonora Beleza, the former Portuguese Minister of Health, recognized APOC
for its “outstanding contribution to the prevention, control, and fight against onchocer-
ciasis. . .bringing health and hope to the poorest of the poor, especially those living in the
remotest and underserved regions of Africa.” APOC and the Foundation decided to
channel the €1 million through the Trust Fund to ensure equitable distribution to the
beneficiaries of the APOC program.
Strengthening the institutional reach
In 2011, the Sabin Vaccine Institute, through a grant provided by the Global Network for
Neglected Tropical Diseases, contributed US$1.2 million to the Trust Fund. In the words
of Foundation President Ambassador Michael Marine, the aim is to “assist APOC’s ef-
forts to include co-implementation of interventions against other preventable NTDs,
and to facilitate institutional linkages around NTDs within the Africa region, especially
with WHO/AFRO.” The subsequent success of this component has shown how the Trust
Fund can be effective in supporting the implementation work of APOC within the
broader regional leadership of WHO/AFRO.
Broadening and extending the scope of APOC
In 2012, the Trust Fund welcomed Sightsavers as its newest contributor. This interna-
tional civil society organization, based in the UK and formerly known as the Royal Com-
monwealth Society for the Blind, has a long history with APOC as a member of the
NGDO group. “We wanted to help APOC in its move to address other preventable
NTDs, especially trachoma,” explained Sightsavers CEO Caroline Harper, “and decided
the most effective way to do this was to step up to become for the next few years one of
the contributors to the Trust Fund.” Sightsavers is the first of the donors to formally
commit to supporting APOC beyond 2015.
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There is a burgeoning movement led by philanthropists and civil society within Africa to con-
tribute to Africa’s challenges. This interest is mirrored by government actions that recognize
that disease is a shared problem and look beyond borders to support solutions. There are also
some novel uses of the existing APOC Trust Fund to channel resources to a broader range of
partners and to address NTD issues beyond onchocerciasis, such as supporting regional efforts
to establish mapping and surveillance mechanisms.
Going forward, the key challenges for funding onchocerciasis control and elimination are to
increase government commitments in the longer term, to convert this to government owner-
ship, and to sustain resources in the interim while the countries gear up to address the chal-
lenges of onchocerciasis elimination and establish programs that address the NTDs more
broadly [19,20]. A particular challenge will be identifying where the experience of APOC can
contribute to integrating the many existing and planned NTD programs and activities.
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